Recent findings have shown that around 2–3% of NSCLC patients develop resistance to EGFR‐targeted therapies by undergoing histological transformation to small‐cell lung cancer (SCLC; Sequist et al, 2011). This evidence concerns the gene EGFR and non-small cell lung carcinoma.